Thinking of joining a study?

Register your interest

NCT02478931 | RECRUITING | Cancer


Study of Personalized Cancer Therapy to Determine Response and Toxicity
Sponsor:

Species name

Information provided by (Responsible Party):

Species name

Brief Summary:

The purpose of this study is to learn more about personalized cancer therapy including response to treatment and side effects. Information about the tests and treatments a person received, or will receive, for their cancer will be collected from medical records to help the researchers determine whether or not patients respond better when their physicians choose to treat them according to the genetic makeup of their tumor. Optional research tests may be performed on tissue, body cavity fluid, blood or urine provided, discarded biological samples taken during routine care that would normally be disposed of and not saved, or on blood samples collected for this study. These research tests will be used to create a "profile" of the collected specimens which will describe unique characteristics about the genes involved in a person's cancer. The tests will also help researchers look for biomarkers that may help predict how people respond to treatment.

Condition or disease

Cancer

Detailed Description:

This is a correlative study of personalized medicine with retrospective and prospective components. Patient medical records will be examined for results of molecular profiling obtained through standard of care testing to help understand, in a descriptive fashion, how well molecular testing might predict response to therapy. Patient outcome parameters including, but not limited to, tumor response, time to treatment failure, patient survival, and toxicity will be analyzed, as well as pharmacodynamic (PD) and pharmacokinetic (PK) data when available. This study will also include optional research-related testing of tissue, blood, or urine specimens via a variety of simple or advanced techniques such as molecular, proteomic, and metabolic analyses for biomarker discovery or for PK and PD parameters. These specimens will be obtained from clinical specimens archived by UCSD Health System Pathology or from specimens collected via an existing IRB-approved protocol, discarded specimens, or from specimens collected for this protocol.

Study Type : OBSERVATIONAL
Estimated Enrollment : 10000 participants
Official Title : UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)
Actual Study Start Date : 2013-09-05
Estimated Primary Completion Date : 2025-09-05
Estimated Study Completion Date : 2026-09-05

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 7 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Must be willing to provide informed consent, parent permission, or assent
Exclusion Criteria
  • * Subjects unable to give informed consent, parent permission, or assent

Study of Personalized Cancer Therapy to Determine Response and Toxicity

Location Details

NCT02478931


Please Choose a site



How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


RECRUITING

United States, California

UCSD Moores Cancer Center

THE JOLLA, California, United States, 92093

RECRUITING

United States, California

Eisenhower Medical Center, Lucy Curci Cancer Center

Rancho Mirage, California, United States, 92270

RECRUITING

United States, California

Rady Children's Hospital, San Diego

San Diego, California, United States, 92123

Loading...